Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07092605
EARLY_PHASE1

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

Sponsor: AgelessRx

View on ClinicalTrials.gov

Summary

The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.

Official title: Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures: For Use in Healthy Individuals Ages 18-65 Who Seek to Improve Their Health and Longevity Through Low-dose (Microdosed) GLP1 Receptor Agonists

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2024-11-01

Completion Date

2025-12-01

Last Updated

2025-07-30

Healthy Volunteers

Yes

Interventions

DRUG

GLP-1

Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.

DRUG

Placebo

Sublingual Placebo (weekly) for up to 6 months

Locations (1)

AgelessRx

Ann Arbor, Michigan, United States